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Abstract
We report a case of a 63-year-old Caucasian female referred to the cornea service of Clinica
Oculistica with a neurotrophic corneal ulcer, decreased corneal sensitivity, absent corneal
reflex, and decreased lacrimation. The medical record review was relevant for mastectomy and
adjuvant therapy for breast cancer complicated by pontocerebellar angle metastasis. Eye
patching and application of antibiotic and vitamin ointments were prescribed at first, without a
significant improvement. Thus, treatment with autologous serum was started. In about two
weeks, the cornea recovered and visual acuity improved with a residual corneal scarring.
Finally, we should mention that, in our case, the main cause of the neurotrophic corneal ulcer
could be identified in the previous trigeminal damage at the pontocerebellar angle and
trigeminal ganglion. Sensory nerves play an important regulatory role via neuro-mediators on
corneal wound healing, as denervation may interfere with cellular metabolism and inhibit
mitosis, leading to an epithelial defect even with no direct damage.
Categories: Ophthalmology, Radiation Oncology
Keywords: autologous serum, radiation therapy, brain metastasis, neurotrophic keratitis, trigeminal
neuropathy
Introduction
Neurotrophic keratitis (NK) is a rare corneal disease characterized by a prevalence of less than
5/10,000 in the general population [1]. Damage at any level of the trigeminal nerve from its
cranial nucleus to the corneal nerve endings can cause corneal sensitivity reduction,
spontaneous epithelium breakdown, and impairment of corneal healing leading to the
development of NK [2]. Clinical presentation may be insidious because patients with NK rarely
complain of symptoms, except for blurred vision due to persistent epithelial defects (PED),
corneal stroma scarring, or swelling [1]. We report a case of an oncologic patient who developed
NK after completing radiation therapy for treating a pontocerebellar angle and trigeminal
ganglion metastases. Our purpose is to describe an unusual case of trigeminal neurotrophic
cornea ulcer (TNCU) after a damage to the third nerve and its ganglion.
Case Presentation
A 63-year-old Caucasian female was referred to the cornea service of our clinic complaining
about blurry vision for about one month. Topical broad-spectrum antibiotic drops were
previously prescribed elsewhere for the cornea ulcer she had in her right eye, without
improvement. Our first visual examination revealed a loss of superficial corneal stroma of 5.5
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mm diameter, and staining with fluorescein indicated a 9 mm diameter corneal
disepithelization. We evaluated corneal sensitivity by using a corneal Cochet-Bonnet contact
aesthesiometer and it showed a decreased result. Moreover, the corneal reflex was absent and
lacrimation was decreased in her right eye. The left eye was within normal limits, with no
previous history of eye diseases. Her medical record showed arterial hypertension, anxiety, and
breast cancer complicated by brain metastases. Cancer-related left brachial plexopathy, and
progressive spastic paraparesis due to spinal cord compression occurred secondary to
metastatic brain infiltration (Figure 1). In July 2009, she underwent a right simple mastectomy
with a right axillary lymph node dissection (ALND). Pathology had confirmed an invasive
ductal carcinoma, moderately differentiated, 2.4 cm, estrogen/progesterone receptor negative,
HER2 positive +3, with negative surgical margins. Three out of the eight right axillary lymph
nodes dissected, including the sentinel lymph node, were positive.
The standard of care for a patient with these tumor features is surgery plus adjuvant
chemotherapy and immunotherapy [3]. Thus, in agreement with the National Comprehensive
Cancer Network (NCCN) practice guidelines, combined treatment with trastuzumab and
tamoxifen was started. After seven years of a disease-free interval, in March 2016,
pontocerebellar angle and trigeminal ganglion metastases occurred. Thus, the patient was
assigned to go through a local cytoreductive radiotherapy scheduled as 20 Gy in 5 fx delivered
over one week. One month later, the patient developed a corneal ulcer. At that time, neither
diabetes nor any other co-morbidities were present, and the patient was not taking any other
medications. The treatment was started with eye patching and application of fluoroquinolone
q2h and vitamin ointments with frequent monitoring on an outpatient basis every, one, two
days pending improvement. The corneal ulcer improved after ten days, but it did not heal. A
therapeutic contact lens was then applied but it was not sufficient, with no significant ocular
improvement reported after seven days. Forty percent autologous serum tears (AST) every two
hours was proposed. After obtaining a written informed consent, the patient was tested for
blood-borne infections, including hepatitis B and C, syphilis, and HIV serology. The
venipuncture was performed at the antecubital fossa under aseptic conditions to collect 100 ml
of whole blood into sterile containers. This was left standing for two hours to ensure complete
clotting. The blood was then centrifuged for 15 minutes at 3000 RPM. The serum was then
separated in a sterile manner and diluted to 40% using saline solution. In approximately 15
days, the cornea markedly ameliorated with combined improved in visual acuity. Visual acuity
improved from hand motion to 20/40 (Figure 2). After the treatment, residual corneal scarring
remained in her right eye.
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FIGURE 1: Brain MRI
Post-Gadolinium axial T1-weighted image showing a right paramedian pontine area of contrast
enhancement, at the level of the emergence of the fifth cranial nerve (green arrow).
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FIGURE 2: Corneal healing with autologous serum
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Corneal improvement from day one to day 15 with autologous serum tears with reduction of the
stromal opacity (pictures A to F). Fluorescein stains corneal stroma but not intact corneal
epithelium, thus demarcating the area of the epithelial loss (red arrow). Pictures G to K show
progress in re-epithelialization. Complete re-epithelization is showed by picture L.
Discussion
In our case, the underlying cause of the neurotrophic keratopathy seems to be the cornea
denervation due to the previous trigeminal injury. Sensory nerves could affect the corneal
epithelialization by releasing neuro-mediators, such as acetylcholine, substance P, and
calcitonin gene-related peptide. Their lack, resulting from a denervation, could determine an
epithelial defect even in the absence of direct injury [1, 4].This can be triggered by a myriad of
conditions [5]; in our case damage to the third nerve caused by metastases were probably the
underlying cause of the disease. Radiotherapy delivered directly to the pontocerebellar angle
might also have played a role, even if the occurrence of such radiation-induced damage is rare;
the pathophysiological mechanisms are not yet fully understood, and usually, clinical signs
appear several years afterward [6]. Recently, the use of AST has gained wide acceptance for the
treatment of ocular surface disorders unresponsive to conventional medical therapy [7]. Such
conditions include persistent epithelial defects or severe dry eyes [8]. The serum has
biomechanical and biochemical properties like natural tears [9]. As described in our case and
accordance with the current literature, treatment with AST is safe and no substantial side
effects have been reported [5]. Its neurotrophic support can be explained by its content:
epithelial and neurotrophic growth factors as vitamin A, fibronectin, epidermal growth factor,
transforming growth factor b (TGFb), substance P, and insulin-like growth factor-1 [10]. These
essential components can contribute to healing in cases of PED usually associated with an
already compromised ocular surface. We use a centrifugation rate of 3000 RPM for 15 minutes,
and it results in good separation of serum and blood clot without inducing hemolysis. This g-
force can help to yield a larger volume of serum from a full blood sample, and it can also result
in a lower concentration of TGFb. The latter, if exceeded, can slow down the re-
epithelialization [9]. The efficacy of AST seems to be both dose and concentration-dependent
[9]. In our experience, 40% concentration has proved to be effective.
Conclusions
Our report shows that brain metastasis should always be suspected if TNCU occurs in an
oncology patient. Deeper neurotrophic ulcers can cause serious scarring and cornea
perforation, leading to severe visual impairment; a rapid diagnosis and prompt treatment are
needed to prevent such complications. Topical medication with AST may be a useful therapeutic
option for TNCU after a damage of the Gasser's ganglion.
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